DENVER, Feb. 18 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that it will report 2004 fourth
quarter and year-end results the afternoon of Monday, February 28, 2005.
J. William Freytag, President and CEO, and other members of Myogen's
senior management will provide a company update and discuss results via
webcast and conference call on Monday, February 28, 2005 at 4:30 pm Eastern.
To access the live webcast, please log on to the company's website at
http://www.myogen.com and go to the Investor Relations section. Alternatively,
callers may participate in the conference call by dialing 800-218-8862
(domestic) or 303-262-2131 (international). Webcast and telephone replays of
the conference call will be available approximately two hours after the
completion of the call through Friday, March 11, 2005. Callers can access the
replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international).
The passcode is 11024350#.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and has three
product candidates in late-stage clinical development: enoximone capsules for
the treatment of advanced chronic heart failure, ambrisentan for the treatment
of pulmonary arterial hypertension and darusentan for the treatment of
resistant hypertension. The company, in collaboration with Novartis, also
conducts a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic heart
failure and related cardiovascular disorders. Please visit our website at
http://www.myogen.com.
Safe Harbor Statement
The 2004 results press release and conference call will contain forward-
looking statements that involve significant risks and uncertainties, including
those that can be found in the "Risk Factors" section of Myogen's Form 10-K
for the year ended December 31, 2003, Myogen's Form S-3 filed on October 29,
2004 and in Myogen's periodic reports on Form 10-Q and Form 8-K. Myogen does
not undertake any obligation to update any forward-looking statements
contained in the results press release or the anticipated conference call as a
result of new information, future events or otherwise. The company cautions
investors not to place undue reliance on the forward-looking statements
contained in the press release or the conference call. No forward-looking
statement can be guaranteed and actual events and results may differ
materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
